Kornimate/medical-research-clean huggingface dataset:
virtual reality as a treatment tool for chronic neck pain in patients with fibromyalgia

Conditions: Fibromyalgia

Summary: fibromyalgia (fm) is a disease characterized by widespread pain, fatigue and cognitive alterations, among other symptoms, neck pain being the most frequent and debilitating. virtual reality (vr) has emerged as a breakthrough for the treatment of such chronic conditions. the objective of this study is to evaluate the efficacy of vr in the treatment of chronic neck pain in patients with fm. material and methods: single-blind randomized clinical trial study. patients with fm who meet the inclusion criteria will be recruited and will be distributed into three groups (gc, g1, g2). g1 (vr + cervical mobility exercises), g2 (cervical mobility exercises), control group (cg). the treatment will be administered twice a week for 4 weeks. measurements of variables such as fiq, eq-5d, kinesiophobia, pain (vas and algometer), range of motion (rom), fatigue and adherence to treatment will be performed. a follow-up is intended to be carried out 15 days and a month after the end of the study.

research questions: can virtual reality combined with exercise improve the quality of life and impact of fibromyalgia? can exercise performed with vr improve kinesiophobia, cervical range of motion, and pain? will vr lead to improvements in patients' exercise functional capacity? the aim is to collect a sample of more than 50 patients with fibromyalgia and cervical pain lasting more than three months. variables to be collected include cervical range of motion (measured with goniometry), pain (measured with a visual analog scale and pressure algometry at two cervical points), kinesiophobia (tsk questionnaire), impact of fibromyalgia (fiq), quality of life (eq-5d), fatigue (borg visual scale), disability caused by cervical pain (questionnaire), central sensitization (questionnaire), and functional capacity (measured with the "timed-up and go" physical test). recruitment was conducted through the fibromyalgia and chronic pain association of mostoles. a one-month treatment will be administered with two sessions per week (with at least one day in between), totaling 8 sessions lasting approximately 30 to 40 minutes each. measurements will be taken before starting the treatment, at the end of the treatment, 15 days after completion, and 30 days after completing the entire treatment. subjects will be randomized into three groups: a control group (cg) that will not receive treatment, group 1 (g1) that will receive cervical mobility exercise combined with exercise using virtual reality (vr), and group 2 (g2) that will receive cervical mobility exercise alone.

Eligibility criteria:
inclusion criteria: * fibromyalgia condition * present neck pain during the last 3 months exclusion criteria: * present any pathology that contraindicates the use of virtual reality * being pregnant at the moment of the study. * not accepting the informed consent.

Keywords: virtual reality chronic pain exercises fibromyalgia
similarities and differences of biological therapies for severe asthma.

Conditions: Asthma

Summary: this is an ambispective multicenter longitudinal observational study to evaluate the efficacy and safety profile of biological therapies in patients diagnosed with severe asthma in real life conditions.

the use of biologicals to treat severe asthma has been implemented in a regular basis while information on long term effectiveness and safety is lacking. it is necessary to establish strategies to closely monitor the possible occurrence of reactions, adverse effects of innovative biological medicines used to treat severe asthma. in this study the investigators want to evaluate the comparative effectiveness, utilization patterns, long-term safety, and use in special groups in real-life conditions in severe asthma.

Eligibility criteria:
inclusion criteria: * individuals of any age: adults and children. * diagnosis of severe asthma as given by the treating physician, and defined as an asthma that remains uncontrolled in despite adherence with maximal optimized therapy and treatment of contributed factors, or asthma that worsens when high dose treatment is decreased. * being treated or not (control group) with biological drugs. * signed informed consent. exclusion criteria: * none.
community engagement alliance against disparities

Conditions: Diabetes; Pre-diabetes; Hypertension; Overweight and Obesity

Summary: the community engagement alliance against disparities - washington district of columbia, maryland, virginia (ceal dmv), is a multi-community and multi-university consortium. through collaboration and shared leadership, the ceal-dmv the consortium- comprising five institutions: george washington university, howard university, johns hopkins university, morgan state university, and the university of maryland, baltimore-has established a regional structure for bi-directional community involvement to engender trust and foster communication. each site builds on thriving community partnerships, which have been instrumental in enhancing trust, community capacity, and readiness to reduce health disparities.

the investigators propose to evaluate the effect of a multi-level, community-digital health promotion intervention, compared to delayed control intervention, at improving health and social service utilization, and the prevention and management of hypertension, diabetes, overweight and obesity. the evidence-based intervention is based on substantial evidence supporting the role of community health workers in health promotion and reduction of risks associated with chronic diseases. studies have demonstrated community health worker (chw) intervention success at improving chronic disease risks and management, including for hypertension and diabetes, through support in implementing clinical recommendations, overcoming barriers to lifestyle behavior change, achieving personal goals, and preventing complications. additionally, there is substantial evidence supporting digital approaches for the prevention and management of cardiometabolic diseases. the proposed intervention and methods also build on almost three years of ceal dmv collaboration with community partners. at the community level, core activities will focus on capacity building to ensure the trusted community-based organization partners are fully supported in the implementation of community-digital strategies to address hypertension, diabetes, overweight and obesity.

Eligibility criteria:
inclusion criteria: * self-identify as black or latino * age 18 years or older * reside in defined geographic area * diagnosis of one or more target conditions: prediabetes/diabetes (hba1c 5.7%), hypertension (≥130/80 mm hg), overweight/obesity (bmi \>25 kg/m\^2) exclusion criteria: * unable to provide informed consent * no access to phone/internet

Keywords: ceal-dmv community engagement alliance diabetes hypertension pre-diabetes
canadian registry of icd implant testing procedures

Conditions: Ventricular Fibrillation

Summary: to document practices in canadian icd implant centres around defibrillation therapy efficacy testing.

to document types of defibrillation testing (dft) procedures are in current use in canada, rates of use an dno use of dft testing, medical indications for non use of dft testing, rate of successful testing of first lead configuration, rates and types of complications from dft testing, costs of implant procedures and the costs associated with dft testing, short term outcomes of patients with different types of implant procedures.

Eligibility criteria:
inclusion criteria: * receiving a guidant icd system, including replacements exclusion criteria: * new epicardial lead(s) implanted, included in another cardiovascular trial (may be in the election study)
setrox js master study

Conditions: Cardiac Disease

Summary: the purpose of this study is the evaluation of safety and efficacy of the pacemaker lead "setrox js".


Eligibility criteria:
inclusion criteria: * meet the indications for pacemaker therapy * available for follow-up visits on a regular basis at the investigational site * contractual capability and ability to consent * age ≥18 years exclusion criteria: * meet one or more of the contraindications for pacemaker therapy * permanent atrial fibrillation * have a life expectancy of less than six months * cardiac surgery in the next six months * enrolled in another cardiac clinical investigation * have other medical devices that may interact with the implanted pacemaker * pregnant and breast-feeding women
monocentric perspective study: use of liquid biopsy with diagnostic imaging

Conditions: Breast Cancer; Liquid Biopsy

Summary: evaluation of the diagnostic accuracy of mammography in the morpho-structural analysis of mammographic images in breast cancer-diagnosed patients or patients in follow-up for breast cancer by extracting a number of features describing the texture and morphology of the lesions reported in the form of a structured report explicitly developed for the study. correlation of the data obtained from evaluating the primary endpoint with the genetic/molecular analysis on liquid biopsy.


Eligibility criteria:
inclusion criteria: * full information on the study and signature of the informed consent * biopsy-proven breast cancer or previous surgery for breast cancer * willingness of the patient to undergo liquid biopsy exclusion criteria: * state of pregnancy or breastfeeding * patients operated on for benign or inflammatory diseases
dental biofilm control during orthodontic treatment

Conditions: Gingivitis; Malocclusion

Summary: orthodontic appliances can affect changes in the relationships of members of the oral microbiome. microbiome imbalance can result in oral infections and complicate treatment. the focus is on the microbiological profile of dental biofilm and its control. the effects of metals released by corrosion of alloys for oral use on the microbiome and the extent to which they modify the effectiveness of gingivitis therapy by mechanical and chemical control of biofilm will be investigated. early and late colonizers of the tooth surface will be analyzed. the condition of gingiva will be assessed, and the results will show the specifics of biofilm and gingiva exposed and unexposed, and differences in the response of individual bacteria to therapy. molecular biology techniques will be used to quantify the total bacterial biomass (16s rrna) and the proportion of specific bacterial species within the dental biofilm.

the aim is: * to determine the clinical characteristics of gingiva of subjects not exposed to metals of dental alloys and exposed to metals * characterization of microbiome of dental biofilm in subjects not exposed to metals of dental alloys and exposed to metals and to determine changes in the structure of dental biofilm due to exposure to metals * examine the extent to which environmental influences modify the effectiveness of treatment of gingivitis by mechanical removal of biofilm and chemical control (chlorhexidine digluconate mouthwash (chx)) * to examine the behavior of bacteria of early and late colonizers of dental biofilm after chemical control * to analyze biofilm on metal and non-metal appliance * to explore patient reported outcome measures study design is a randomized controlled trial with 4 parallel groups: (i) fixed metal orthodontic appliance with regular oral hygiene, (ii) fixed metal orthodontic appliance with chx, (iii) non-metal fixed orthodontic appliance with regular oral hygiene, and (iv) non-metal orthodontic appliance with chx.

Eligibility criteria:
inclusion criteria: * malocclusion with moderate or great need for orthodontic treatment (index of orthodontic treatment need grades \>=3) exclusion criteria: * neurodevelopmental disorders * intellectual disability * oligodontia * congenital craniofacial anomalies * orofacial clefts

Keywords: malocclusion gingivitis dental biofilm
assessment of 2 different techniques for suppression of respiratory motion in lung cancer treatment with proton therapy using magnetic resonance imaging (mri)

Conditions: Healthy Volunteers

Summary: since 1996 proton therapy has been applied very successfully at the paul scherrer institute in switzerland to irradiate deep-seated, stationary tumors. in order to treat tumors within an organ which moves due to breathing (e.g. lung) motion mitigation strategies need to be implemented to ensure the precise irradiation of the moving target. the aim of this study is to assess the feasibility and compare (via mri imaging) 2 techniques which "freeze" the movement of the lung by breath hold. one method is suppression of respiratory movement via high-frequency, mechanical ventilation by means of a jet ventilator (hfpv). the other technique is deep inspiration breath-hold (dibh) with hyperventilation and simultaneous inspiration of 100% o2 including daily breath-hold exercise.


Eligibility criteria:
inclusion criteria: * ability to give informed consent by signature * healthy, i.e. normal physical and mental status exclusion criteria: * contraindications to mri (non-mri-suitable electronical \& metal implants, claustrophobia) * women who are pregnant or are breast feeding * acute or chronic illness * known or suspected non-compliance, drug or alcohol abuse * inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant * presence of any psychological or sociological condition potentially hampering compliance with the study protocol

Keywords: breath hold dibh hfpv mri
the relationship between allergic rhinitis and the risk of symptom in patients with mild covid-19

Conditions: COVID-19; Allergic Rhinitis

Summary: at present, most studies mainly focussed on severe patients, and there was no comparison of symptom differences between ar patients and healthy people with mild infection to evaluate the symptoms of ar patients during infection and to provide preventive treatment in advance. so this experiment was designed.

after the end of this large-scale infection, the investigators analyzed the re-diagnosis of patients with allergic rhinitis (ar) at the otolaryngology clinic, and found significant differences in symptoms between ar and non-ar patients. ar patients had more serious nasal and pharyngeal symptoms. in previous studies on the correlation between allergic diseases and covid-19 infection, ar was found to be a protective factor to reduce covid-19 infection and the risk of severe disease . in contrast, a cohort study in south korea found that ar worsened covid-19 infection . these studies mainly focussed on severe patients, and there was no comparison of symptom differences between ar patients and healthy people with mild infection. allergy may lead to the overall damage of nasal mucosa due to the mechanical and immune defense function of the virus. immunotherapy will significantly reduce the number and severity of upper respiratory tract infections (including children's common cold). the investigators hypothesized that ar is more likely to aggravate symptoms after infection, while allergen immunotherapy （ait） may reduce the risk of symptoms as a protective factor for symptoms after ar virus infection. therefore, the investigators conducted a retrospective analysis on the risk of symptoms after covid-19 infection in patients with ar, and compared the difference of symptoms after covid-19 infection in patients with ait and non-ait ar.

Eligibility criteria:
inclusion criteria: * all participants completed at least one antigen or nucleic acid test and the results were positive. * the diagnoses of ar met the international diagnostic standards for ar. the participants had obvious clinical symptoms and the allergen test was positive. exclusion criteria: * suspected new infected person with symptoms（ no antigen or nucleic acid test and the results were nagetive ） * participants requiring icu admission after covid-19 infection-

Keywords: allergic rhinit sublingual immunotherapy the symptoms after covid-19 infection odds ratio
docetaxel with a phytochemical in treating patients with hormone independent metastatic prostate cancer

Conditions: Metastatic Prostate Cancer

Summary: rationale : drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. dietary supplements, such as phytochemicals, may stop or delay the development of prostate cancer.

the purpose of this study is to assess the pathological response rate in metastatic prostate cancer patients treated by : docetaxel with a phytochemical

Eligibility criteria:
inclusion criteria: * age \>18 * who performance status 0-2 * life expectancy ≥ 3 months * patients receiving androgen-suppressive therapy in the form of chirurgical castration by orchiectomy or pulpectomy,or medical by lhrh agonist or antagonist with or without anti-androgen or all treatment blocking non gonadic testosterone fraction * resulting to testosteronemia \<0,5 ng/ml * histologically confirmed adenocarcinomia of prostate cancer and documented hormone independant metastatic disease - defined by: objective progression with at least one measurable lesion and/or evaluable lesion according to recist criteria and /or a rise in psa level ("rising psa") * total bilirubin ≤ upper limit of normal (uln). * ast and alt ≤ 1.5 times uln. alkaline phosphatase ≤ 2.5 times uln. * serum creatinine \ 60 ml/ min. * neutrophil count \> 2.109 l-1. * platelet count ≥ 100,000/mm3. * hemoglobin ≥ 10 g/dl * not previous chemotherapy, except estracyt * no liver, kidney or heart failure link to treatment * no malabsorption syndrome or disease significantly affecting gastrointestinal function * prior radiotherapies are permetted withing four weeks of the first study treatment and must be \< 25 % of the bone marrow, and all adverse events must be resolved * prior surgery are permitted. exclusion criteria: * age \< 18 * history of psychiatric disorders including psychotic disorder, dementia or seizures that would prohibit the understanding, observance and giving of informed consent * previous or concomitant other malignancies except basal or squamous cell carcinoma of the skin or other cancer curatively treated with surgery and/or radiotherapy * patients should not have symptomatic brain metastasis * concurrent severe and/or uncontrolled co-morbid medical condition * malabsorption syndrome or disease significantly affecting gastro-intestinal function or major resection of the stomach, proximal small bowel or grade \> 2 dysphagia * patients with uncontrolled infection * history of significant neurologic (i.e. peripheral neuropathy grade \> 2 using nci-ctc criteria v3.0) * patients should not have received nsaids or cox2 inhibitors within the three weeks prior to starting the study * treatment with any investigational drug within 30 days prior to registration * patients should not have current regimen containing dietary phytonutrients
effect of nociception level monitoring during remimazolam-based total intravenous anesthesia on intraoperative opioid requirements and postoperative pain

Conditions: Adult Patients Aged 19-64, Scheduled for Elective Arthroscopic Knee Surgery

Summary: this study aims to investigate whether the use of nociception monitoring during general anesthesia with remimazolam-based total intravenous anesthesia has an effect on intraoperative opioid requirements and postoperative pain. this study is a randomized trial with a 50% probability of being assigned to either group. randomization will be done by an anesthesiologist not involved in anesthesia or postoperative outcome assessment. patients and the investigator in charge of postoperative outcomes assessment will be blinded to group allocation.


Eligibility criteria:
inclusion criteria: adult patients between 19 and 64 years of age, asa class i\~iii, scheduled for arthroscopic knee surgeryunder general anesthesia. exclusion criteria: patient refusal, patients unable to read consent form, active uri or uncontrolled asthma, pneumonia, history of allergies to benzodiazepines, decreased liver or kidney function, heart failure of ejection fraction\<55%, pregnant or breastfeeding patients, history of substance abuse/addiction
the effect of extract of green tea on obese women and obese related hormone peptides

Conditions: Diabetes Mellitus; Hyperlipidemia

Summary: the aim of this study is to examine the therapeutic effect of green tea extract on obese women and the correlation analysis between traditional chinese medicine syndrome and obese related hormone peptides.

obesity has become a noticeable and worldwide public health problem recently. according to the who survey in 2005, 1.6 billion and 400 million adults were found overweight and obese, respectively. in taiwan, there are more than 30% found overweight in the national survey in 2009. compare with the ones done in 1999 and 2005, a rising trend of the prevalence of obesity is found. furthermore, the incidence and prevalence of obesity are also increasing worldwide, especially in the developing and newly industrialized nations. in addition, obesity is related to some chronic diseases, like diabetes mellitus, hyperlipidemia and cardiovascular diseases, which are major lethal health concerns in taiwan and many developing countries. taken together, obesity emerges as an important issue lately. the aim of the study is to evaluate the therapeutic effect and safety of green tea extract on demographic characteristics and obesity-related hormone peptide of obese women and to establish an obesity traditional chinese medicine (tcm) syndromes questionnaire, which will undergo well assessing of reliability and validity. second, we intent to utilize the tcm syndromes and quality of life (sf-12, who) questionnaire to 200 obesity women for the correlation analysis of tcm syndromes, obesity related hormone peptides and quality of life. the results of this study are expected to assess the effect and safety of green tea extract on obese women and improve the scientific diagnosis of tcm with a quantitative measurement by this questionnaire.

Eligibility criteria:
inclusion criteria: * aged between 20 and 60 years old women * chinese * body mass index (bmi) \> 27 kg/m2 * waist circumference (wc) \> 80 cm * willing to participate in and fill out the questionnaires for this trial. exclusion criteria: * gpt \> 80 u/l, serum creatinine \> 2.0 mg/dl * breast feeding or pregnancy * heart failure * acute myocardial infarction * stroke * any other conditions not suitable for trial as evaluated by the physician

Keywords: diabetes mellitus hyperlipidemia green tea epigallocatechin gallate